An inhibitor of glycosphingolipid metabolism is used as a chemotherapeutic agent against cancer or to treat other conditions caused by cell proliferation sensitive glycosphingolipid metabolism inhibition. A preferred inhibitor is 1-phenyl-2-acylamino-3-morpholino-1-propanol.

The present invention relates to odor eliminating compositions, including air fresheners, and methods of eliminating odors. The inventive compositions comprise soyaethyl morpholinium ethosulfate, benzethonium chloride, and Ordenone.sup..RTM..

##STR1## Benzenesulfonamides of formula (I), in which W is OR.sub.1, NR.sub.2 OR.sub.1, NR.sub.A R.sub.B, NR.sub.2 NR.sub.A R.sub.B, or NR.sub.2 (CH.sub.2).sub.2-4 NR.sub.A R.sub.B and the other variables as defined in the claims, are inhibitors of MEK and are effective in the treatment of proliferative diseases, cancer, stroke, heart failure, xenograft rejection, arthritis, cystic fibrosis, hepatomegaly, cardiomegaly, Alzheimer's disease, complications of diabetes, septic shock, and viral infec...

There are provided according to the invention, novel compounds of formula (I) ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, X, a, b and Z are as defined in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

The present invention concerns morpholinyl containing benzimidazoles having inhibitory activity on the replication of the respiratory syncytial virus and having the formula ##STR00001## a prodrug, N-oxide, addition salt, quaternary amine, metal complex or stereochemically isomeric form thereof wherein G is a direct bond or optionally substituted C.sub.1-10alkanediyl; R.sup.1 is Ar.sup.1 or a monocyclic or bicyclic heterocycle Q is R.sup.7, pyrrolidinyl substituted with R.sup.7, piperidinyl subst...

The present invention includes methods for treatment and prophylaxis of conditions associated with lactosylceramide. The methods generally provide for administration to a mammal, particularly a human, of a therapeutically effective amount of a compound that increases enzymatic activity of UDPGal:GlcCer.beta.1.fwdarw.4 galactosylceramide (GalT-2). In vitro and in vivo assays for detecting compounds with therapeutic capacity to modulate GalT-2 are also provided.

Aminocycloalkyl cinnamide compounds (I) are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses a variety of in vitro and in vivo uses for the compounds and compositions, including the treatment of arrhythmia and the production of local analgesia and anesthesia. n=1 4; R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.13, X and A are as in claim (1).

The invention relates to new arylglycinamide derivatives of general formula I ##STR1## and the pharmaceutically acceptable salts thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and Ar have the meanings given in the specification, and the preparation and use thereof. The new compounds are valuable neurokin (tachykinin) antagonists.

The invention relates to the use of p-chloro-N-(2-morpholinoethyl)benzamide in the treatment of anxiety disorders, such as, panic disorders, social phobia and obsessive compulsive disorder,

The present invention relates to compounds of formula (I) ##STR1## wherein X is --NR.sup.6 R.sup.7 or C-- or N-linked imidazolyl; Y is hydrogen or C.sub.1-4 alkyl optionally substituted by hydroxy; R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are selected from a variety of suitable aromatic substituents; R.sup.6 is hydrogen, C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkylC.sub.1-4 alkyl, phenyl, or C.sub.2-4 alkyl substituted by C.sub.1-4 alkoxy or hydroxy; R.sup.7 is hydrogen, C.s...